Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

AIM: Inhibition of heat shock protein (Hsp90) has been proven to be effective in overriding primary and acquired resistance of kinase inhibitors. In this study, we investigated the role of FS-108, a newly developed Hsp90 inhibitor, to overcome gefitinib resistance in EGFR mutant non-small cell lung...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Pharmacol Sin
Main Authors: Wang, Yue-qin, Shen, Ai-jun, Sun, Jing-ya, Wang, Xin, Liu, Hong-chun, Zhang, Min-min, Chen, Dan-qi, Xiong, Bing, Shen, Jing-kang, Geng, Mei-yu, Zheng, Min, Ding, Jian
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5260832/
https://ncbi.nlm.nih.gov/pubmed/27616574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2016.85
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados